Health Care [ 9/12 ] | Biotechnology [ 65/74 ]
NASDAQ | Common Stock
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide.
Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5336 and ABI-1179, which are in Phase 1a/1b clinical studies for recurrent genital herpes; ABI-4334, a capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus that is in Phase 1b clinical study; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study.
The company also develops ABI-7423, an oral broad-spectrum non-nucleoside polymerase inhibitor that targets transplant-related herpesviruses.
It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies.
The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014.
Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 6, 25 | -1.17 Increased by +29.52% | -1.60 Increased by +26.88% |
| Mar 26, 25 | -1.57 Increased by +26.98% | -1.75 Increased by +10.29% |
| Nov 6, 24 | -1.51 Decreased by -459.26% | -2.02 Increased by +25.25% |
| Aug 8, 24 | -2.05 Decreased by -540.62% | -2.23 Increased by +8.07% |
| May 8, 24 | -1.66 Decreased by -348.65% | -3.23 Increased by +48.61% |
| Jan 31, 24 | -2.15 Decreased by -367.39% | -2.88 Increased by +25.35% |
| Nov 8, 23 | -0.27 Increased by +43.75% | -0.23 Decreased by -17.39% |
| Aug 9, 23 | -0.32 Increased by +37.25% | -0.29 Decreased by -10.34% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 7.36 M Increased by +2.71% | -10.34 M Increased by +5.72% | Decreased by -140.48% Increased by +8.21% |
| Sep 30, 24 | 6.84 M Increased by +N/A% | -9.61 M Increased by +33.34% | Decreased by -140.44% Decreased by N/A% |
| Jun 30, 24 | 8.53 M Increased by +N/A% | -11.15 M Increased by +34.00% | Decreased by -130.69% Decreased by N/A% |
| Mar 31, 24 | 5.79 M Increased by +N/A% | -9.08 M Increased by +50.51% | Decreased by -156.91% Decreased by N/A% |
| Dec 31, 23 | 7.16 M Increased by +N/A% | -10.96 M Increased by +49.32% | Decreased by -153.04% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -14.42 M Increased by +37.00% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -16.90 M Increased by +30.61% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -18.34 M Increased by +20.33% | Decreased by N/A% Decreased by N/A% |